Clinical trials: Hepatocellular Carcinoma Resectable
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
We adopted the prospective cohort study to compare the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody in the treatment of advanced unresectable liver…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade
- Trial name
- NCT04997850
- Testing
- lenvatinib + sindilimab/carrelizumab, TACE
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinrui Zhu，MD
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable…
- Trial name
- MORNING-RWS (NCT07064681)
- Testing
- Surgery with and without the aid of Indocyanine Green (ICG)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization…
- Trial name
- NCT06904196
- Testing
- Lenvatinib plus SIRT, Lenvatinib
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE)…
- Trial name
- NCT06916546
- Testing
- SIRT-L-P, TACE-L-P
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
Currently in France, hepatocellular carcinoma (HCC) represents over 30% of indications of liver transplantation (LT) (# 500 cases/year).
- Trial name
- Ta-Len-Tra (NCT05901194)
- Testing
- Lenvatinib
- Where
- 6 sites in France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Solid Tumor
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients…
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
- Trial name
- MYCHELANGELO I (NCT05497453)
- Testing
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two
- Where
- 15 sites in United States, Hong Kong and 3 more
- Volunteers
- 24 people
- Sponsor
- Omega Therapeutics
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Patients suffering from advanced stage hepatocellular carcinoma (HCC) who have shown disease progression during lenvatinib-based first line treatment, will be enrolled in this trial.
- Trial name
- NCT04511455
- Testing
- Cabozantinib
- Where
- 10 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…
- Trial name
- NCT06492395
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-Resectable
Y-90 SIRT for Unresectable HCC Larger Than 7cm
This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy.
- Trial name
- NCT06707233
- Testing
- SIRT
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-Resectable
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
The goal of this clinical trial is to determine if the addition of biodegradable magnesium metal microspheres to traditional TACE (Transarterial Chemoembolization) is effective in treating hepatocellular carcinoma, and to assess…
- Trial name
- NCT06779461
- Testing
- Magnesium Microspheres, cTACE
- Where
- 10 sites in China
- Volunteers
- 228 people
- Sponsor
- InnoBM Pharmaceuticals Co., Ltd.
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China.
- Trial name
- NCT06712017
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence
- Trial name
- NCT04701060
- Testing
- Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
Resectable Hepatocellular Carcinoma
Neoadjuvant Triple Therapy for Resectable HCC
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple…
- Trial name
- TALENP001 (NCT06569498)
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma Non-resectable
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
This study was designed to evaluate the effectiveness and safety of mFOLFOX7（Oxaliplatin,Calcium Levofolinate,Fluorouracil） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT06607107
- Testing
- mFOLFOX7 combined with Camrelizumab and apatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma Non-resectable
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy…
- Trial name
- NCT06561399
- Testing
- TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- Fujian Provincial Hospital